Education
About Us
Working with TipRanks
Follow Us
Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
Total Valuation
Galectin Therapeutics has a market cap or net worth of $370.11M. The enterprise value is $242.83M.
Market Cap$370.11M
Enterprise Value$242.83M
Share Statistics
Galectin Therapeutics has 64,479,210 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64,479,210
Owned by Insiders28.72%
Owned by Institutions1.11%
Financial Efficiency
Galectin Therapeutics’s return on equity (ROE) is 0.46 and return on invested capital (ROIC) is -1316.98%.
Return on Equity (ROE)0.46
Return on Assets (ROA)-2.69
Return on Invested Capital (ROIC)-1316.98%
Return on Capital Employed (ROCE)2.37
Revenue Per Employee0.00
Profits Per Employee-3.14M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Galectin Therapeutics is ―. Galectin Therapeutics’s PEG ratio is -0.63.
PE Ratio―
PS Ratio0.00
PB Ratio-0.78
Price to Fair Value-0.78
Price to FCF-1.92
Price to Operating Cash Flow-11.97
PEG Ratio-0.63
Income Statement
In the last 12 months, Galectin Therapeutics had revenue of 0.00 and earned -47.05M in profits. Earnings per share was -0.76.
Revenue0.00
Gross Profit-37.00K
Operating Income-42.43M
Pretax Income-47.05M
Net Income-47.05M
EBITDA-41.47M
Earnings Per Share (EPS)-0.76
Cash Flow
In the last 12 months, operating cash flow was -30.62M and capital expenditures 0.00, giving a free cash flow of -30.62M billion.
Operating Cash Flow-30.62M
Free Cash Flow-30.62M
Free Cash Flow per Share-0.47
Dividends & Yields
Galectin Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.85
52-Week Price Change170.56%
50-Day Moving Average5.41
200-Day Moving Average3.24
Relative Strength Index (RSI)58.31
Average Volume (3m)341.94K
Important Dates
Galectin Therapeutics upcoming earnings date is Mar 26, 2026, TBA (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Galectin Therapeutics as a current ratio of 0.49, with Debt / Equity ratio of -98.94%
Current Ratio0.49
Quick Ratio0.49
Debt to Market Cap1.32
Net Debt to EBITDA-2.20
Interest Coverage Ratio-7.66
Taxes
In the past 12 months, Galectin Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Galectin Therapeutics EV to EBITDA ratio is -4.14, with an EV/FCF ratio of -4.11.
EV to Sales0.00
EV to EBITDA-4.14
EV to Free Cash Flow-4.11
EV to Operating Cash Flow-4.11
Balance Sheet
Galectin Therapeutics has $11.53M in cash and marketable securities with $122.31M in debt, giving a net cash position of -$110.79M billion.
Cash & Marketable Securities$11.53M
Total Debt$122.31M
Net Cash-$110.79M
Net Cash Per Share-$1.72
Tangible Book Value Per Share-$1.65
Margins
Gross margin is 16.67%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin16.67%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Galectin Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside5.08% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast18.82%